What is the optimal dose of cyclobenzaprine (Flexeril) for acute low back pain?

Optimal Dosing of Cyclobenzaprine for Low Back Pain

For acute low back pain, start with cyclobenzaprine 5 mg three times daily, which provides equivalent efficacy to 10 mg three times daily but with significantly less sedation. 1

Dosing Recommendations by Formulation

Immediate-Release Cyclobenzaprine (Standard Flexeril)

• Recommended dose: 5 mg three times daily 1
• Alternative: 10 mg three times daily if 5 mg is insufficient, though this increases sedation risk 1
• Avoid 2.5 mg three times daily - this dose was not significantly more effective than placebo 1
• Duration: Limit to 2-3 weeks maximum 2

Extended-Release Cyclobenzaprine

• Initial dose: 15 mg once daily 3
• Can increase to 30 mg once daily if needed 3
• Take at approximately the same time each day 3
• May be taken with or without food (food increases absorption by 20-35% but doesn't alter efficacy profile) 3

Evidence Supporting Lower-Dose Immediate-Release

The 5 mg three times daily regimen is the optimal balance of efficacy and tolerability. Two large placebo-controlled trials demonstrated that cyclobenzaprine 5 mg TID achieved significantly higher efficacy scores than placebo on all primary measures (patient global impression of change, medication helpfulness, and relief from pain; P ≤ 0.001), with efficacy equivalent to 10 mg TID but lower sedation rates 1. Onset of relief occurred within 3-4 doses of the 5 mg regimen 1.

Comparative Efficacy of Extended-Release Formulations

Both 15 mg and 30 mg once-daily extended-release formulations demonstrated efficacy superior to placebo 4, 5:

• CER 30 mg showed more consistent benefits across multiple measures at day 4, including global impression of change (P = 0.008), relief of local pain (P = 0.004), and restriction of movement (P = 0.002) 5
• CER 15 mg showed significant improvement in medication helpfulness (P = 0.018-0.025) 4, 5
• Median time to "a lot" or "complete" relief: 5-6 days for both doses versus 8 days for placebo 6

Safety Profile Comparison

Extended-release formulations cause significantly less somnolence than immediate-release:

• Somnolence rates: CER 15 mg (0.8%), CER 30 mg (1.6%) versus immediate-release 10 mg TID (7.3%; P < 0.05) 4, 5
• Most common adverse effects across all formulations: dry mouth, dizziness, fatigue, constipation 3, 1
• All adverse events were predominantly mild in intensity 4, 1

Critical Caveats

Skeletal muscle relaxants as a class show no compelling evidence of superiority over placebo when combined with NSAIDs. A 2022 analysis of 4 randomized trials found no statistically significant difference between cyclobenzaprine and placebo when both groups received NSAIDs, with cyclobenzaprine actually showing more adverse effects (P < 0.01) 7. This suggests the benefit may be modest at best.

Guidelines recommend skeletal muscle relaxants only for short-term relief (2-3 weeks maximum) due to lack of long-term efficacy and safety data 2. Extended courses should be reserved only for patients showing clear continued benefit without major adverse events 2.

First-line therapy should be acetaminophen or NSAIDs, not muscle relaxants. The American College of Physicians/American Pain Society guidelines position skeletal muscle relaxants as an option for short-term relief but emphasize that acetaminophen or NSAIDs are first-line medication choices 2.

Practical Algorithm

1. Start with NSAID or acetaminophen alone 2
2. If inadequate relief after 2-3 days, add cyclobenzaprine 5 mg TID (immediate-release) 1
3. Alternative: Cyclobenzaprine ER 15 mg once daily if once-daily dosing preferred and sedation is a concern 4, 5
4. If insufficient response after 3-4 days on 5 mg TID, consider increasing to 10 mg TID or switching to CER 30 mg daily 3, 1
5. Discontinue after 2-3 weeks regardless of response 2
6. Reassess if no improvement within 7 days and consider alternative therapies 2